People with chronic kidney disease should be offered statins, says NICE

27 July 2017

The UK’s National Institute for Health and Care Excellence (NICE) – has published a final standard, which aims to improve the assessment and management of chronic kidney disease (CKD) in adults.

The final quality standard says all adults with CKD should be offered statins, specifically atorvastatin, (the now off-patent former blockbuster Lipitor from US pharma giant Pfizer (NYSE: PFE), as a way to manage their increased risk of cardiovascular disease (CVD).

CKD is a long-term condition where the kidneys no longer work as well as they used to. It is associated with ageing. Around 2.6 million people in England have CKD1 and around 60,000 people die prematurely each year because of the disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK